Tag Archives: DIA
DIA: Does Six Sigma Stifle R&D Innovation?
Can the management style known as Six Sigma help improve the probability of a drug’s commercial success, or do its black-belted acolytes punch holes in the creative process needed for innovative R&D discovery?
Pharma and Cloud Computing: Are We There Yet?
In the past few years, Microsoft has been working hard to create clinical trial platforms for the pharmaceutical industry. This year, the Redmond, WA-based behemoth has moved full-speed ahead with its virtual-server system, dubbed Azure.
Microsoft is not only working on hosted applications, instead the company has established a massive online server or “cloud” that forms [...]
Industry and FDA Brace for Change
While the convention floor of the 46th annual meeting of the Drug Information Association bustled with the usual vendors touting the latest and greatest clinical trial technology, the panels (particularly those that featured FDA members) had a remarkably somber tone.
The main refrain was: “Things are going to change and everyone must step up or get [...]
Posted in Regulatory, Strategy Also tagged Clinical trial, Evidence-based medicine, Janet Woodcock, Pharmaceutical drug, Randomized controlled trial, Research 1 Comment
Hamburg Delivers DIA Keynote
FDA Commissioner Margaret Hamburg delivered this year’s keynote speech in front of a packed room of pharma and bioscience personnel at the 46th annual meeting of the Drug Information Association, which opened Monday morning. Hamburg started her speech by explaining how her earliest goal as FDA chief was to build the field of regulatory [...]

DIA: Social Media Guidelines are DDMAC’s "Highest Priority"